Aoxing Pharmaceutical Company, Inc. (AOXG) Stock

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a specialized drug manufacturer primarily operating within the People's Republic of China. The company dedicates itself to the research, development, production, and distribution of pharmaceutical products, with a strong emphasis on narcotics, pain management solutions, and addiction treatments. Its current product portfolio includes Zhongtong'an, a capsule derived from herbal extracts used for relieving oral and dental discomfort; Yiqi Qiangshen Granule, an over-the-counter herbal preparation designed to invigorate qi, strengthen the body, and improve blood flow by clearing meridian blockages; and Tilidine hydrochloride. The latter is an oral synthetic narcotic analgesic tablet, available in 50mg or 100mg doses, prescribed for the alleviation of acute, moderate to severe pain, as well as chronic pain associated with cancer. Aoxing also boasts several promising products in its development pipeline. These include Oxycodone and Acetaminophen tablets and capsules, which have successfully completed clinical trials for both acute and chronic pain management. Another is Buprenorphine/Naloxone, a sublingual combination tablet that has finished Phase II clinical trials as a treatment for opioid dependence. Furthermore, a Tilidine/Naloxone compound capsule is currently undergoing Phase II clinical trials, targeting acute and chronic pain. Initially known as China Aoxing Pharmaceutical Company, Inc., the firm rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010. Its corporate headquarters are situated in Shijiazhuang, China.

Aoxing Pharmaceutical Company, Inc. (AOXG) stock trades at $0.00 with a market capitalization of $266756. The stock is valued at a price-to-earnings (P/E) ratio of -86.98, price-to-book of 0.01, price-to-sales of 0.04. Over the past 52 weeks the stock has ranged between $0.00 and $0.01, and currently trades 100.0% below its 52-week high.

On profitability, Aoxing Pharmaceutical Company, Inc. generates a return on equity (ROE) of -7.56%, return on capital employed of 280.61%, an operating margin of 15.41%, a net profit margin of -4.86%.

Official website: axzyen.icm.cn